ENZN

Enzon Pharmaceuticals, Inc.
CAPPED RATING

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Enzon Pharmaceuticals, Inc. (ENZN) is rated D+ (1.8/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Value (C+); its weakest is Momentum (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
C+
Factor Score 2.6 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
D-
Factor Score 0.8 / 5.0
Revisions
D+
Factor Score 1.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA 135.7
Rev Growth YoY N/A
Gross Margin 15.3%
Price Return 3M -15.7%
Price Return 12M -85.5%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 3.9
ROE -30.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2025-03-31 C+ (2.6) C+ (2.5) D+ (1.7) D- (0.8) D+ (1.5) D+ (1.8)
2024-06-30 F (0.3) C+ (2.5) C- (1.9) D- (0.8) D (1.5) D (1.4)